FDA re­vis­es and ex­pands draft guid­ance on ad­just­ing for co­vari­ates in RCTs

The FDA on Thurs­day re­vised and ex­pand­ed a 2019 draft guid­ance that spells out how to ad­just for co­vari­ates in the sta­tis­ti­cal analy­sis of ran­dom­ized con­trolled tri­als (RCTs).

Build­ing on the ICH’s E9 guide­line on the sta­tis­ti­cal prin­ci­ples for clin­i­cal tri­als, the 3-page draft has been trans­formed in­to an 8-page draft, with more de­tailed rec­om­men­da­tions on lin­ear and non­lin­ear mod­els to an­a­lyze the ef­fi­ca­cy end­points in RCTs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.